Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
One Percent Rule Checklist For Safer Forex Trading Risk 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
LEIDEN, the Netherlands, April 10, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
A live webcast of the event will be accessible in the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
